Business
Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes
– Dr. Gary Goldenberg appointed Chief Medical Officer; Dr. Brad Catalone assumes the role of Head of Drug Development – – New leadership strengthens expertise
About this update from Verrica Pharmaceuticals Inc.
[{"type":"text","content":"– Dr. Gary Goldenberg appointed Chief Medical Officer; Dr. Brad Catalone assumes the role of Head of Drug Development –\n – New leadership strengthens expertise in Clinical, Chemistry, Manufacturing, and Controls (CMC), and Regulatory Affairs – WEST CHESTER, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced key appointments to its drug development team. Current Board of Directors (the “Board”) member Dr. Gary Goldenberg, a renowned thought leader in the field of dermatology, is stepping down to become Verrica’s Chief Medical Officer, effective August 1, 2020. Verrica announced separately today that Dr. Lawrence Eichenfield is joining the Board on August 1, 2020, replacing Dr. Goldenberg. In addition, Dr. Brad Catalone is being appointed to the newly created position of Head of Drug Development on that same date. “Our new colleagues bring a wealth of expertise that strengthens our drug development team in ways that are critical for the next stage of growth,” said Ted White, Verrica’s President and Chief Executive Officer. “Dr. Goldenberg’s previous role as a member of our Board, as well his experience in academia and as a practicing dermatologist, gives him familiarity with our strategy and deep expertise to help lead our clinical programs as Chief Medical Officer. We are also excited to welcome Dr. Brad Catalone, whose CMC, regulatory affairs, and medical devices expertise will be of vital importance to Verrica in the coming months and years. Having these prominent industry leaders join Verrica at this time underscores the potential value of our pipeline and the strength of our science.” As Chief Medical Officer, Dr. Goldenberg will oversee medical affairs and all aspects of clinical development and strategy related to Verrica’s product candidates, as well as provide scientific guidance for potential business development initiatives. He joined Verrica’s Board in May 2018. He is an Assistant Professor of Dermatology and Pathology at The Icahn Sinai School of Medicine at Mount Sinai Hospital in New York City. Prior, he was Director of Dermatopathology at University of Maryland School of Medicine. Dr. Goldenberg is board certified in dermatology and dermatop...